Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ALK rearrange ALK V1180L||lung non-small cell carcinoma||predicted - resistant||Alectinib||Clinical Study - Cohort||Actionable||In a retrospective study, ALK V1180L was identified in 11% (5/46) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received Alecensa (alectinib) treatment (PMID: 31358542).||31358542|
|ALK rearrange ALK V1180L||lung non-small cell carcinoma||predicted - resistant||Alectinib||Case Reports/Case Series||Actionable||In a clinical study, ALK V1180L was identified in post-progression biopsies of 2 non-small cell lung cancer patients harboring an ALK rearrangement after Alecensa (alectinib) treatment (PMID: 29935304).||29935304|
|ALK rearrange ALK V1180L||lung non-small cell carcinoma||predicted - sensitive||Brigatinib||Case Reports/Case Series||Actionable||In a clinical study, Alunbrig (brigatinib) treatment resulted in 1 partial response and 1 stable disease in a total of 2 patients with Alecensa (alectinib)-refractory, ALK-rearranged non-small cell lung cancer with an acquired ALK V1180L (PMID: 29935304).||29935304|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|